THE ARISING · Editorial evidence note
An Early Eye Trial Tests the Safety of Partial Reprogramming
Life Biosciences reported preliminary observations in three people with glaucoma. The trial has not shown that the treatment restores vision.
Partial reprogramming aims to change how cells use their genes without turning them into a different kind of cell. The clinical question is whether such a change can help a damaged tissue recover function without causing harm. In a 2020 study, researchers reported improvements in measures of vision in aged mice and in a mouse model of glaucoma. That was a reason to investigate the approach, not evidence that it works in people.
Life Biosciences announced on June 9, 2026, that the first participant had received ER-100 in its phase 1 study. The study includes people with open-angle glaucoma and people with another optic nerve condition caused by interrupted blood flow. Its main purpose is to assess safety and tolerability. On October 8, the company reported no serious adverse events or dose-limiting toxicities through 56 days in the first three glaucoma participants. Two showed improvements on visual-field testing, which measures how well someone sees across different parts of their field of view. With three participants and no control group, the observation does not establish that the treatment caused the changes.
Eight weeks also cannot answer longer-term safety questions. A separate mouse study using a different reprogramming approach found tumors, a reason to monitor that possibility rather than an estimate of ER-100’s cancer risk. The registered eye trial plans follow-up through five years.
The milestone that would change the clinical picture is a controlled study showing that people see better for longer, alongside evidence that the benefits outweigh the risks.
Registered phase 1 trial · June first-participant announcement · October sponsor interim report · Mouse vision study · Separate mouse safety study